What was the overall market valuation of the US human insulin market in 2024?

The overall market valuation was $507.15 Million in 2024. Read More

What is the projected market valuation for the US human insulin market by 2035?

The projected valuation for 2035 is $768.6 Million. Read More

What is the expected CAGR for the US human insulin market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 3.85%. Read More

Which companies are considered key players in the US human insulin market?

Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Baxter International, Mylan, and Teva Pharmaceutical Industries. Read More

What are the revenue ranges for different types of insulin in the US market?

Revenue ranges for insulin types include Rapid Acting Insulin at $80.0 - $120.0 Million, Short Acting Insulin at $70.0 - $100.0 Million, Intermediate Acting Insulin at $90.0 - $130.0 Million, Long Acting Insulin at $100.0 - $150.0 Million, and Premixed Insulin at $167.15 - $268.6 Million. Read More

How does the distribution channel impact the US human insulin market?

Distribution channels show revenue ranges with Retail Pharmacy at $250.0 - $400.0 Million, Hospital Pharmacy at $80.0 - $120.0 Million, Online Pharmacy at $50.0 - $100.0 Million, and Clinical Settings at $127.15 - $148.6 Million. Read More

What are the revenue projections for different formulations of insulin?

Formulation revenues include Vial at $100.0 - $150.0 Million, Pen at $150.0 - $250.0 Million, Cartridge at $120.0 - $200.0 Million, and Disposable Pens at $137.15 - $168.6 Million. Read More

What therapeutic areas are covered in the US human insulin market?

Therapeutic areas include Type 1 Diabetes with revenues of $100.0 - $150.0 Million, Type 2 Diabetes at $300.0 - $500.0 Million, and Gestational Diabetes at $107.15 - $118.6 Million. Read More

How does the US human insulin market compare to its projected growth by 2035?

The market is expected to grow from $507.15 Million in 2024 to $768.6 Million by 2035, indicating a robust growth trajectory. Read More

What factors may influence the growth of the US human insulin market in the coming years?

Factors influencing growth may include advancements in insulin formulations, increasing diabetes prevalence, and the strategic initiatives of key players like Eli Lilly and Company and Novo Nordisk. Read More

US Human Insulin Market

ID: MRFR/Pharma/11949-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Human Insulin Market Research Report: Size, Share, Trend Analysis By Types (Rapid Acting Insulin, Short Acting Insulin, Intermediate Acting Insulin, Long Acting Insulin, Premixed Insulin), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Clinical Settings), By Formulation (Vial, Pen, Cartridge, Disposable Pens) and By Therapeutic Area (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Rapid Acting Insulin
  2. 4.1.2 Short Acting Insulin
  3. 4.1.3 Intermediate Acting Insulin
  4. 4.1.4 Long Acting Insulin
  5. 4.1.5 Premixed Insulin
2. 4.2 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.2.1 Hospital Pharmacy
  2. 4.2.2 Retail Pharmacy
  3. 4.2.3 Online Pharmacy
  4. 4.2.4 Clinical Settings
3. 4.3 Pharmaceutical, BY Formulation (USD Million)
  1. 4.3.1 Vial
  2. 4.3.2 Pen
  3. 4.3.3 Cartridge
  4. 4.3.4 Disposable Pens
4. 4.4 Pharmaceutical, BY Therapeutic Area (USD Million)
  1. 4.4.1 Type 1 Diabetes
  2. 4.4.2 Type 2 Diabetes
  3. 4.4.3 Gestational Diabetes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novo Nordisk (DK)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sanofi (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Baxter International (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Mylan (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Teva Pharmaceutical Industries (IL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
4. 6.4 US MARKET ANALYSIS BY FORMULATION
5. 6.5 US MARKET ANALYSIS BY THERAPEUTIC AREA
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY FORMULATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY FORMULATION, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  3. 7.2.3 BY FORMULATION, 2025-2035 (USD Million)
  4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

Rapid Acting Insulin
Short Acting Insulin
Intermediate Acting Insulin
Long Acting Insulin
Premixed Insulin

Pharmaceutical By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Clinical Settings

Pharmaceutical By Formulation (USD Million, 2025-2035)

Vial
Pen
Cartridge
Disposable Pens

Pharmaceutical By Therapeutic Area (USD Million, 2025-2035)

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”